The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
Patients with type 2 diabetes (T2D) have a higher risk of heart failure (HF) than healthy people, and the prognosis of patients with diabetes and current or previous HF is worse than that of patients with only diabetes. We reviewed the HF outcomes in recently published cardiovascular outcome trials...
Main Authors: | Xiaohui Pan, Shishi Xu, Juan Li, Nanwei Tong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2020.599355/full |
Similar Items
-
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
by: Giuseppe Palmiero, et al.
Published: (2021-05-01) -
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
by: Natalia G. Vallianou, et al.
Published: (2021-06-01) -
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
by: Arnold, S.V, et al.
Published: (2022) -
Heart failure hospitalization with DPP-4 inhibitors: A systematic review and meta-analysis of randomized controlled trials
by: Awadhesh Kumar Singh, et al.
Published: (2019-01-01) -
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
by: Dario Giugliano, et al.
Published: (2021-09-01)